Physician profile
Astrid Hoffmann-Olsen
NPI 1497859581
$7,162.32
in general payments reported to CMS, 2019-2025
31 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $695 · 2021: $823 · 2022: $1,040 · 2023: $802 · 2024: $966 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.94 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.90 | 2019-2024 | |
| Astellas Pharma US INC | $1,002.33 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $792.40 | 2021-2025 | Bijuva |
| Therapeuticsmd, INC. | $513.29 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $504.49 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $342.58 | 2019-2025 | |
| Biogen, INC. | $328.33 | 2024-2025 | Zurzuvae |
| Urovant Sciences INC | $305.63 | 2021-2022 | |
| Exeltis, USA INC. | $287.14 | 2019-2025 | Slynd |
| Exact Sciences Corporation | $285.52 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $227.59 | 2019-2025 | |
| Millicent US INC | $194.05 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Myovant Sciences INC. | $160.27 | 2021-2022 | |
| Evofem Biosciences, INC. | $124.18 | 2020-2022 | |
| Avion Pharmaceuticals | $121.28 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $104.04 | 2019-2025 | Paragard T 380a |
| Vertical Pharmaceuticals, LLC | $83.03 | 2019 | |
| Agile Therapeutics, INC. | $80.76 | 2021 | |
| Scynexis, INC. | $78.16 | 2022 | |
| Mission Pharmacal Company | $66.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.16 | 2019-2023 | Gardasil 9 |
| Aspira Women'S Health INC | $54.36 | 2024-2025 | Ova1 |
| Organon LLC | $47.52 | 2022 | |
| Allergan, INC. | $46.50 | 2019-2020 | |
| Daiichi Sankyo INC. | $31.93 | 2019 | |
| Medicem INC. | $23.16 | 2020 | |
| Innovation Technologies INC | $17.12 | 2025 | Irrisept |
| Duchesnay USA Incorporated | $16.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.72 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.26 | 2019 | |
| Lupin INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Hoffmann-Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.